Cancer Immunology Immunotherapy

Founding Editor
G. Mathé

Other Biological Response Modifications

Volume 35 1992

Editors in Chief

R. W. Baldwin **E. Mihich**

Editorial Board

F. Balkwill London
J. Bennett Albany, NY
N. Bloksma Utrecht
H. Blythman Basel
R. Bolhuis Rotterdam
V. S. Byers Nottingham
T. Carey Ann Arbor, MI
M. Cheever Seattle, WA
M. Colnaghi Milan
S. Dray Chicago, IL
S. Eccles Sutton, Surrey
M. J. Ehrke Buffalo, NY
M. Fopp St. Gallen
E. Grimm Houston, TX
K. Hellström Seattle, WA
K. Höffken Essen
A. Houghton New York, NY
H. Kirchner Heidelberg
E. Kleinerman Houston, TX
W. Knapp Vienna
H. Kobayashi Sapporo
M. Mastrangelo Philadelphia, PA
J. McVie London
M. Mitchell Los Angeles, CA
M. Moore London
R. J. North Saranac Lake, NY
G. Parmiani Milan
M. Price Nottingham
R. Rees Sheffield
R. A. Reisfeld La Jolla, CA
H. F. Sewell Nottingham
K. Sikora London
Z. Steplewski Philadelphia, PA
G. Stevenson Southampton
J. Talmadge Omaha, NE
E. Tsubura Osaka
A. Uchida Kyoto
F. Vánky Stockholm
E. Vitetta Dallas, TX
B. Vose Cheshire

Springer International

Cancer Immunology Immunotherapy

Other Biological Response Modifications

This journal was founded in 1976. Founding editor: G. Mathé
Editors: R. W. Baldwin, E. Mihich
Published by Springer International

Copyright

Submission of a manuscript implies: that the work described has not been published before (except in the form of an abstract or as part of a published lecture, review, or thesis); that it is not under consideration for publication elsewhere; that its publication has been approved by all coauthors, if any, as well as by the responsible authorities at the institute where the work has been carried out; that, if and when the manuscript is accepted for publication, the authors agree to automatic transfer of the copyright to the publisher; and that the manuscript will not be published elsewhere in any language without the consent of the copyright holders.

All articles published in this journal are protected by copyright, which covers the exclusive rights to reproduce and distribute the article (e. g., as offprints), as well as all translation rights. No material published in this journal may be reproduced photographically or stored on microfilm, in electronic data bases, video disks, etc., without first obtaining written permission from the publisher.

The use of general descriptive names, trade names, trademarks, etc., in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.

While the advice and information in this journal is believed to be true and accurate at the date of its going to press, neither the authors, the editors, nor the publisher can accept any legal responsibility for any errors or omissions that may be made. The publisher makes no warranty, express or implied, with respect to the material contained herein.

Special regulations for photocopies in the USA: Photocopies may be made for personal or inhouse use beyond the limitations stipulated under Section 107 or 108 of U. S. Copyright Law, provided a fee is paid. This fee is US $ 0.20 per page per copy, plus a basic fee of US $ 2.00 per article. All fees should be paid to the Copyright Clearance Center, Inc., 21 Congress Street, Salem, MA 01970, USA, stating the ISSN 0340-7004, the volume, and the first and last page numbers of each article copied. The copyright owner's consent does not include copying for general distribution, promotion, new works, or resale. In these cases, specific written permission must first be obtained from the publisher.

Printed in Germany by E. Kieser GmbH Graphischer Betrieb, D-8902 Neusäß bei Augsburg

© Springer-Verlag Berlin Heidelberg 1992

Contents of volume 35

No. 1 (pp 1–74) published April 1992
No. 2 (pp 75–150) published May 1992
No. 3 (pp 151–224) published July 1992
No. 4 (pp 225–296) published August 1992
No. 5 (pp 297–364) published September 1992
No. 6 (pp 365–430) published October 1992

Abbondanza A → Battelli MG
Abe H, Tani T, Shibata J, Kodama M: Induction of antitumor activities in spleen cells from mice and rats activated with lipopolysaccharide immobilized on beads 39
Abe R → Arinaga S
Abu-hadid MM → Chakravarty PK
Ackerstein A → Morecki S
Adachi M → Inoue H
Adachi Y → Sasaoki T
Adler R → Hurwitz E
Aggarwal BB → Ioannides CG
Ahmed T → Mittelman A
Akaza H → Kawai K
Akiyoshi T → Arinaga S
Akiyoshi T → Inoue H
Allavena P →Apiranthitou-Drogari M
Aninipot RL → Boerman OC
Announcement: 1993 Keystone Symposia Meetings 364
Antognetti G → Reilly EB
Apiranthitou-Drogari M, Paganin C, Bernasconi S, Losa G, Maneo A, Colombo N, Mantovani A, Allavena P: In search of specific cytotoxic T lymphocytes infiltrating or accompanying human ovarian carcinoma 289
Arii S → Sasaoki T
Arinaga S → Inoue H
Arinaga S, Karimine N, Takamuku K, Nanbara S, Inoue H, Abe R, Watanabe D, Matsuoka H, Ueo H, Akiyoshi T: Correlation of eosinophilia with clinical response in patients with advanced carcinoma treated with low-dose recombinant interleukin-2 and mitomycin C 246
Arlin Z → Mittelman A
Armstrong C → Koo AS
Ashby JA → Park KGM
Azuma E → Komada Y

Baader P → Handgretinger R
Bagash J → Young MRI
Baldwin RW → Byers V
Ballou B, Jaffe R, Persiani S, Shen W-C, Langone JJ, Sands H, Reilandu JM, Curley J, Hakala TR: Tissue localization of methotrexate-monoclonal-IgM immunoconjugates: anti-SSEA-1 and MOPC 104E in mouse teratocarcinomas and normal tissues 251
Bando T → Chai J-G
Barber SR, Werdel J, Symbula M, Williams J, Burkett BA, Taylor PT, Roche JK, Crum CP: Seroreactivity to HPV-16 proteins in women with early cervical neoplasia 33
Basse P, Herberman RB, Hokland M, Goldfarb RH: Reply to the Letter to the editors by A. Maghazachi 428
Bateman WJ → Morris AG
Battelli MG, Abbondanza A, Tazzari PL, Bolognesi A, Lemoli RM, Stirpe F: T lymphocyte killing by a xanthine-oxidase-containing immunotoxin 421
Baum RP → Fischer P
Baxevanis CN → Papanastasiou M
Bear HD → Inge TH
Belldegrun A → Koo AS
Berki T, Németh P: Photo-immunotargeting with haematoporphyrin conjugates activated by a low-power He-Ne laser 69
Bernasconi S → Apiranthitou-Drogari M
Bethke KP → Inge TH
Bigler RD → Hubbell HR
Blumenthal RD → Boerman OC
Bochner B → Koo AS
Boeckmann W → Fischer P
Boerman OC, Sharkey RM, Wong GY, Blumenthal RD, Aninipot RL, Goldenberg DM: Influence of antibody protein dose on therapeutic efficacy of radioiodinated antibodies in nude mice bearing GW-39 human tumor 127
Bolognesi A → Battelli MG
Bright RK → Mernaugh RL
Bronte V → Zanovello P
Brown RS → Yang FE
Brusa P, Dosio F, Pietribiasi F, Delprino L, Feraiorni P, Mariani M, Bussolati G, Cattel L: Antitumour activity of a sterically blocked ricin immunotoxin on a human colorectal adenocarcinoma grafted subcutaneously in nude mice 373
Burkett BA → Barber SR
Bussolati G → Brusa P
Byers V, Levin AS, Ozanoff D, Baldwin RW: Reply to the comment on the interpretation of lymphocyte phenotyping 221

Calvo B → Hand PH
Carter CRD, Hancock BW, Rees RC: The augmentation of lymphokine-activated killer activity following pulsing of human peripheral blood mononuclear cells with recombinant human interleukin-2 264
Carter WA → Hubbell HR
Cattel L → Brusa P
Cerundolo V → Zanovello P
Chai J-G, Bando T, Kobashi S, Oka M, Nagasawa H, Nakai S, Maeda K-I, Himeno K, Sato M, Ohkubo S: An extract of seeds from *Aeginetia indica* L., a parasitic plant, induces potent antigen-specific antitumor immunity in Meth A-bearing BALB/c mice 181
Chakravarty PK, Fuji H, Abu-hadid MM, Hsu S-C, Sood AK: Tumorigenicity of interleukin-2 (IL-2)-cDNA-transfected L1210 lymphoma and its in vivo variants is modulated by changes in IL-2 expression; potential therapeutic implications 347
Chang CC → Zhai Y-F
Chao K-C → Lee C-YG
Chao T-Y → Yang KD
Chen KW → Lee C-YG
Cheng S-N → Yang KD
Chong AS-F, Staren ED, Scuderi P: Monoclonal antibodies anti-CD3, anti-TCRαβ and anti-CD2 act synergistically with tumor cells to stimulate lymphokine-activated killer cells and tumor-infiltrating lymphocytes to secrete interferon γ 335
Clavo AC → Yang FE
Collavo D → Zanovello P
Collinson AR → Rasmussen RA
Colombo N → Apiranthitou-Drogari M
Coogan M → Young MRI
Counts SL → Rasmussen RA
Crum CP → Barber SR
Curley J → Ballou B

Daculsi R → Vaillier D
Darley RL → Morris AG
Delprino L → Brusa P
Derbyshire EJ, Stahel RA, Wawrzynczak EJ: Cytotoxic properties of a ricin A chain immunotoxin recognising the cluster-5A antigen associated with human small-cell lung cancer 417
Dopfer R → Handgretinger R
Dosio F → Brusa P
Dueck M → Schlag P

Egawa K → Tanino T
Eremin O → Park KGM
Esselman WJ → Zhai Y-F
Estabrook A → Leon JA

Feraiorni P → Brusa P
Finch M → Hand PH
Fischer P, Baum RP, Tauber M, Boeckmann W, Weier S, Scherberich JE: Immunoscintigraphic localization of renal tumours in an extracorporeal perfusion model with a monoclonal antibody against γ-glutamyltransferase 283
Fisher PB → Leon JA
Fisk B → Ioannides CG
Frank JL → Inge TH
Franks CR → Park KGM
Freedman RS → Ioannides CG
Frödin J-E → Ragnhammar P
Fuji H → Chakravarty PK
Fujiwara H → Zou J-P
Fujiwara M → Tomita Y
Fukushima H → Misaki T
Funaki N → Sasaoki T

Gansow O → Hand PH
Garmestani K → Hand PH
Gazit Z, Weiss DW, Shouval D, Yechezkeli M, Schirrmacher V, Notter M, Walter J, Kedar E: Chemo-adoptive immunotherapy of nude mice implanted with human colorectal carcinoma and melanoma cell lines 135
Gerneth T → Schlag P
Gibson GD → Hubbell HR
Golan DE → Green LC

Goldenberg DM → Boerman OC
Goldfarb RH → Basse P
Gonen B, Kahana O, Witz IP: In vivo tumorigenicity and in vitro sensitivity to tumor-necrosis-factor α mediated killing of c-Ha-*ras*-transformed cells 388
Green LC, Waldman RH, Golan DE: Comment on the interpretation of lymphocyte phenotyping 218
Gualde N → Vaillier D
Gutierrez MC → Leon JA

Hakala TR → Ballou B
Hamaoka T → Zou J-P
Hanada M → Komada Y
Hancock BW → Carter CRD
Hand PH, Calvo B, Milenic D, Yokota T, Finch M, Snoy P, Garmestani K, Gansow O, Schlom J, Kashmiri SVS: Comparative biological properties of a recombinant chimeric anti-carcinoma mAb and a recombinant aglycosylated variant 165
Handgretinger R, Baader P, Dopfer R, Klingebiel T, Reuland P, Treuner J, Reisfeld RA, *Niethammer D: A phase I study of neuroblastoma* with the anti-ganglioside GD2 antibody *14.G2a 199*
Hayes PD → Park KGM
Herberman RB → Basse P
Herfarth C → Schlag P
Heys SD → Park KGM
Hidaka A → Misaki T
Higashituji H → Sasaoki T
Himeno K → Chai J-G
Hjelm A-L → Ragnhammar P
Hohenberger P → Schlag P
Hokland M → Basse P
Holán V → Kikuchi A
Holland JF → Kikuchi T
Hoover SK → Inge TH
Hosokawa M → Micallef M
Hsu S-C → Chakravarty PK
Hubbell HR, Vargas HE, Tsujimoto KL, Gibson GD, Pequignot EC, Bigler RD, Carter WA, Strayer DR: Antitumor effects of interleukin-2 and mismatched double-stranded RNA, individually and in combination, against a human malignant melanoma *xenograft 151*
Hurwitz E, Adler R, Shouval D, Takahashi H, Wands JR, Sela M:

Immunotargeting of daunomycin to localized and metastatic human colon adenocarcinoma in athymic mice 186
Iida Y → Misaki T
Ikegame K → Zou J-P
Inge TH, Hoover SK, Frank JL, Kawabata TT, Bethke KP, Bear HD: Enhancement of cytotoxic T lymphocyte growth from *spleens of P815-tumor-bearing host mice* with mafosfamide 119
Inoue H → Arinaga S
Inoue H, Adachi M, Karimine N, Arinaga S, Ueo H, Korenaga D, Akiyoshi T: Immunohistochemical analysis of lymphocyte subsets *infiltrating* gastric carcinoma after mitomycin C administration 297
Ioannides CG, Fisk B, Tomasovic B, Pandita R, Aggarwal BB, Freedman RS: Induction of interleukin-2 receptor by tumor necrosis factor α on cultured ovarian tumor-associated lymphocytes 83
Itai S → Sasaoki T
Itoh K → Salmeron MA

Jackson GA → Yang FE
Jaffe R → Ballou B
Jiang H → Leon JA
Jiao H, Shen W, Ohe Y, Miura K, Tamura T, *Saijo N: A new 3-(4,5-dimethylthiazol-2-*yl)-2,5-diphenyltetrazolium bromide (MTT) *assay for testing macrophage cytotoxicity to* L1210 and its drug-resistant cell lines in *vitro 412*

Kahana O → Gonen B
Karimine N → Arinaga S
Karimine N → Inoue H
Kasagi K → Misaki T
Kashmiri SVS → Hand PH
Kawabata TT → Inge TH
Kawai K, Sasaki T, Saijo-Kurita K, Akaza H, Koiso K, Ohno T: Additive effects of antitumor drugs and lymphokine-activated *killer cell cytotoxic activity in tumor cell kil*ling determined by lactate-dehydrogenase-*release assay 225*
Kedar E → Gazit Z
*Kedar E, Rutkowski Y, Leshem B: Chemo-*Immunotherapy of murine solid tumors: enhanced *therapeutic effects by interleukin-2* combined with interferon α and the role of *specific T cells 63*
Kempeni J → Moritz T
Kennedy RC → Mernaugh RL
Kikuchi A, Holán V, Minowada J: Effects of *tumor necrosis factor α, interferon α,* and inteferon γ on non-lymphoid leukemia cell lines: growth inhibition, differentiation induction and drug sensitivity modulation 257
Kikuchi T, Ohnuma T, Holland JF, Spitler LE: Penetration of anti-melanoma immunotoxin into multicellular tumor spheroids and cell kill effects 302
Klein E → Vánky F
Klingebiel T → Handgretinger R
Kloke O → Moritz T
Kobashi S → Chai J-G
Kobayashi H → Micallef M
Kobayashi H → Tomita Y
Kodama M → Abe H
Koiso K → Kawai K
Komada Y, Zhang SL, Zhou Y-W, Hanada M, Shibata T, Azuma E, Sakurai M: Cellular immunosuppression in children with acute lymphoblastic leukemia: effect of consolidation chemotherapy 271
Kondoh Y → Ogoshi K
Konishi J → Misaki T
Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso C-L, deKernion JB, Belldegrun A: Interleukin-6 and renal cell cancer: production, regulation, and growth effects 97
Koral KF → Yang FE
Korenaga D →Inoue H
Kumazawa E, Tohgo A, Soga T, Kusama T, *Osada Y: Significant antitumor effect of a* synthetic lipid A analogue, *DT-5461,* on *murine syngeneic tumor models 307*
Kummer G → Moritz T
Kusama T → Kumazawa E

Laatikainen A, Schultz-Suhonen L, Mänty-*järvi R: Effect of interferon γ on the sensitiv*ity of bovine-papilloma-virus (BPV1)-transformed cell lines to cell-mediated cytotoxicity 205
Lambert JM → Rasmussen RA
Lanford RE → Mernaugh RL
Langone JJ → Ballou B
Lee C-S → Yang KD
Lee C-YG, Chen KW, Sheu FS, Tsang A, Chao K-C, Ng H-T: Studies of a tumor-associated antigen, COX-1, recognized by a monoclonal antibody 19
Lemoli RM → Battelli MG
Leon JA, Gutierrez MC, Jiang H, Estabrook A, Waxman S, Fisher PB: Modulation of *the antigenic phenotype of human breast* carcinoma cells by modifiers of protein *kinase C activity and recombinant human* interferons 315
Leshem B → Kedar E
Levin AS, → Byers V
Liebrich W → Schlag P
Losa G → Apiranthitou-Drogari M

Maeda K-I → Chai J-G
Maghazachi AA: Confusion about the tissue distribution of lymphokine-activated killer (LAK) cells 426
Manasterski M → Schlag P
Mandruzzato S → Zanovello P
Maneo A → Apiranthitou-Drogari M
Mantovani A → Apiranthitou-Drogari M
Mäntyjärvi R → Laatikainen A
Mariani M → Brusa P
Masucci G → Ragnhammar P
Matsuoka H → Arinaga S
Meeting announcements 224
Mellstedt H → Ragnhammar P
Mernaugh RL, Shearer MH, Bright RK, Lanford RE, Kennedy RC: Idiotype network components are involved in the murine immune response to simian virus 40 large tumor antigen 113
Micallef M, Hosokawa M, Togashi Y, Kobayashi H: Rat macrophage activation after treatment with the bleomycin group of *antitumour antibiotics in vivo 106*
Milenic D → Hand PH
Minowada J → Kikuchi A
Misaki T, Watanabe Y, Iida Y, Hidaka A, Kasagi K, Fukushima H, Konishi J: Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy 92
Mitomi T → Ogoshi K
Mittelman A, Urban R, Wong G, Ahmed T, Arlin Z: Phase I trial of ImuVert (natural membrane vesicles associated with ribosomes) in patients with advanced cancer 331
Miura K → Jiao H
Monden K → Sasaoki T
Morecki S, Revel-Vilk S, Nabet C, Pick M, *Ackerstein A, Nagler A, Naparstek E,* Shahar MB, Slavin S: Immunological evaluation of patients with hematological malig-

nancies receiving ambulatory cytokine-mechabed immunotherapy with recombinant human interferon-α2a and interleukin-2 401
Morita T → Salmeron MA
Moritz T, Kloke O, Nagel-Hiemke M, Kummer G, Wandl UB, Opalka B, Plappert B, Kempeni J, Seeber S, Niederle N: Tumor necrosis factor α modifies resistance to interferon α in vivo: first clinical data 342
Morris AG, Darley RL, Bateman WJ: The loss of class II MHC antigen expression by *ras*-transformed murine fibroblasts passaged as tumours correlates with increased tumorigenicity but is not mediated by T cells 46
Morton H → Quinn KA
Murray JB → Park KGM

Nabet C → Morecki S
Nagasawa H → Chai J-G
Nagel-Hiemke M → Moritz T
Nagler A → Morecki S
Nakai S → Chai J-G
Nakanishi-Ito C → Tanino T
Nanbara S → Arinaga S
Naparstek E → Morecki S
Németh P → Berki T
Ng H-T → Lee C-YG
Niederle N → Moritz T
Niethammer D → Handgretinger R
Nishiyama T → Tomita Y
Notter M → Gazit Z

Oakley CS → Zhai Y-F
Ogoshi K, Kondoh Y, Tajima T, Mitomi T: Glycosidically bound sialic acid levels as a predictive marker of postoperative adjuvant therapy in gastric cancer 175
Ohe Y → Jiao H
Ohkubo S → Chai J-G
Ohno T → Kawai K
Ohnuma T → Kikuchi T
Oka M → Chai J-G
Okazaki T → Tanino T
Opalka B → Moritz T
Osada Y → Kumazawa E
Ozanoff D → Byers V

Paganin C → Apiranthitou-Drogari M
Pandita R → Ioannides CG
Papamichail M → Papanastasiou M
Papanastasiou M, Baxevanis CN, Papamichail M: Promotion of murine antitumour activity by prothymosin α treatment: I. Induction of tumoricidal peritoneal cells producing high levels of tumour necrosis factor α 145
Park KGM, Heys SD, Murray JB, Hayes PD, Ashby JA, Franks CR, Eremin O: Recombinant interleukin-2 treatment in patients with metastatic colorectal cancer: effect on natural cytotoxicity 53
Pequignot EC → Hubbell HR
Persiani S → Ballou B
Pick M → Morecki S
Pietribiasi F →Brusa P
Plappert B → Moritz T
Platsoucas CD → Salmeron MA

Quinn KA, Morton H: Effect of monoclonal antibodies to early pregnancy factor (EPF) on the in vivo growth of transplantable murine tumours (34: 265–271) 223

Ragnhammar P, Masucci G, Frödin J-E, Hjelm A-L, Mellstedt H: Cytotoxic functions of blood mononuclear cells in patients with colorectal carcinoma treated with mAb 17-1A and granulocyte/macrophage-colony-stimulating factor 158
Rasmussen RA, Counts SL, Lambert JM, Collinson AR: Blocked ricin-conjugated T cell immunotoxins: effect of anti-CD6-blocked ricin on normal T cell function 355
Rees RC → Carter CRD
Reilandu JM → Ballou B
Reilly EB, Antognetti G: GD3-reactive antibodies can inhibit the lysis of autologous tumor cells by tumor-infiltrating lymphocytes 59
Reisfeld RA → Handgretinger R
Reuland P → Handgretinger R
Revel-Vilk S → Morecki S
Roche JK → Barber SR
Rosato A → Zanovello P
Rutkowski Y → Kedar E
Ryoyama K: Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide 7

Saijo N → Jiao H
Saijo-Kurita K → Kawai K
Sakurai M → Komada Y
Salmeron MA, Morita T, Seki H, Platsoucas CD, Itoh K: Lymphokine production by human melanoma tumor-infiltrating lymphocytes 211
Sands H → Ballou B
Sasaki T → Kawai K
Sasaoki T, Arii S, Monden K, Itai S, Adachi Y, Funaki N, Higashituji H, Tobe T: Enhancement of rat hepatic macrophages by treatment with interleukin-2 and streptococcal preparation OK432, with reference to antitumor activity, soluble factor production and la expression 75
Sato M → Chai J-G
Sato S → Tomita Y
Scherberich JE → Fischer P
Schirrmacher V → Gazit Z
Schirrmacher V → Schlag P
Schlag P, Manasterski M, Gerneth T, Hohenberger P, Dueck M, Herfarth C, Liebrich W, Schirrmacher V: Active specific immunotherapy with Newcastle-disease-virus-modified autologous tumor cells following resection of liver metastases in colorectal cancer. First evaluation of clinical response of a phase II-trial 325
Schlom J → Hand PH
Schultz-Suhonen L → Laatikainen A
Scuderi P → Chong AS-F
Seeber S → Moritz T
Seki H → Salmeron MA
Sekimata M → Tanino T
Sela M → Hurwitz E
Seo N → Tanino T
Shahar MB → Morecki S
Shaio M-F → Yang KD
Sharkey RM → Boerman OC
Shearer MH → Mernaugh RL
Shen W → Jiao H
Shen W-C → Ballou B
Sheu FS → Lee C-YG
Shibata J → Abe H
Shibata T → Komada Y
Shimabukuro T → Koo AS
Shimizu J → Zou J-P
Shouval D → Gazit Z
Shouval D → Hurwitz E
Slavin S → Morecki S
Snoy P → Hand PH
Soga T → Kumazawa E
Sood AK → Chakravarty PK
Spitler LE → Kikuchi T
Stahel RA → Derbyshire EJ
Staren ED → Chong AS-F
Stirpe F → Battelli MG
Stone RM → Yang KD
Strayer DR → Hubbell HR
Symbula M → Barber SR

Tajima T → Ogoshi K
Takahashi H → Hurwitz E
Takamuku K → Arinaga S
Takiuchi H → Zou J-P
Tamura T → Jiao H
Tani T → Abe H
Tanino T, Seo N, Okazaki T, Nakanishi-Ito C, Sekimata M, Egawa K: Detection of allogeneic Qa/TL and Ly specificities on murine tumor cells with IgD in tumor-regressor serum 230
Tauber M → Fischer P
Taylor PT → Barber SR
Tazzari PL → Battelli MG
Tobe T → Sasaoki T
Togashi Y → Micallef M
Tohgo A → Kumazawa E
Tomasovic B → Ioannides CG
Tomita Y, Watanabe H, Kobayashi H, Nishiyama T, Tsuji S, Fujiwara M, Sato S: Interferon γ but not tumor necrosis factor α decreases susceptibility of human renal cell cancer cell lines to lymphokine-activated killer cells 381
Treuner J → Handgretinger R
Tsang A → Lee C-YG
Tso C-L → Koo AS
Tsuji S → Tomita Y
Tsujimoto KL → Hubbell HR

Ueo H → Arinaga S
Ueo H → Inoue H
Urban R → Mittelman A

Vaillier D, Daculsi R, Gualde N: Effects of lipopolysaccharide on interleukin-2-induced cytotoxic activity of murine splenocyte cultures: role of prostaglandin E_2 and interferons 395
Vánky F, Wang P, Klein E: The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells 193
Vargas HE → Hubbell HR

Wahl RL → Yang FE
Waldman RH → Green LC

Walter J → Gazit Z
Wandl UB → Moritz T
Wands JR → Hurwitz E
Wang P → Vánky F
Watanabe O → Arinaga S
Watanabe H → Tomita Y
Watanabe Y → Misaki T
Wawrzynczak EJ → Derbyshire EJ
Waxman S → Leon JA
Weier S → Fischer P
Weiss DW → Gazit Z
Welsch CW → Zhai Y-F
Werdel J → Barber SR
Williams J → Barber SR
Witz IP → Gonen B
Wong G → Mittelman A
Wong GY → Boerman OC
Wright MA → Young MRI

Yang FE, Brown RS, Koral KF, Clavo AC, Jackson GA, Wahl RL: Quantitative autoradiographic evaluation of the influence of protein dose on monoclonal antibody distribution in human ovarian adenocarcinoma xenografts 365
Yang KD, Stone RM, Lee C-S, Chao T-Y, Cheng S-N, Shaio M-F: Effect of picibanil *(OK432) on neutrophil-mediated antitumor* activity: implication of monocyte-derived neutrophil-activating factors 277
Yechezkeli M → Gazit Z
Yokota T → Hand PH
Young ME → Young MRI
Young MRI, Wright MA, Coogan M, Young *ME, Bagash J: Tumor-derived cytokines* induce bone marrow suppressor cells that mediate immunosuppression through transforming growth factor β 14

Zanovello P, Rosato A, Bronte V, Mandruzzato S, Cerundolo V, Collavo D: Antitumour efficacy of lymphokine-activated killer cells loaded with ricin against experimentally induced lung metastases 27
Zhai Y-F, Esselman WJ, Oakley CS, Chang *CC, Welsch CW: Growth of MCF-7 human* breast carcinoma in severe combined im*munodeficient mice: growth suppression by* recombinant interleukin-2 treatment and role of lymphokine-activated killer cells 237
Zhang SL → Komada Y
Zhou Y-W → Komada Y
Zou J-P, Shimizu J, Ikegame K, Takiuchi H, *Fujiwara H, Hamaoka T: Tumor-im*munotherapy with the use of tumor-antigen-pulsed antigen-presenting cells 1
deKernion JB → Koo AS
mediated immunotherapy with recombinant human interferon-α2a and interleukin-2 401